ORLANDO—Patients with metastatic renal cell carcincoma (RCC) who develop hand-foot syndrome (HFS) while being treated with sunitinib may have better progression-free survival and overall survival than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback